Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2011/09/002033
CTRI/2011/09/002033
Completed
Phase 1

A Phase I clinical trial to assess safety and immune response of Trivalent, Live Attenuated Seasonal Influenza vaccine of SIIL in Adults.

Serum Institute of India Ltd Pune India0 sites40 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Serum Institute of India Ltd Pune India
Enrollment
40
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Serum Institute of India Ltd Pune India

Eligibility Criteria

Inclusion Criteria

  • •Normal healthy subjects of 18\-49 years age

Exclusion Criteria

  • •1\. Confirmed/suspected influenza infection or any influenza vaccination.2\. Have a known allergy to eggs. 3\. Pregnancy and breastfeeding women 4\. Subject participating in other clinical trial 5\. Altered immune status. 6\. Acute febrile illness or acute infectious disease. 7\. Any nasal pathology. 8\. Asthma. 9\. History of allergic reaction. 10\. History of serious chronic illness. 11\. Guillain\-Barré Syndrome.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Phase I clinical trial to assess safety and immunogenicity of an MVA-based influenza H5 vaccine in healthy adultsfluInfluenza10047438
NL-OMON38408Erasmus MC, Universitair Medisch Centrum Rotterdam27
Recruiting
Not Applicable
A Phase I trial to assess safety and immunogenicity of i.d. DNA priming and i.m. MVA boosting in healthy volunteers in MozambiqueHIV/AIDS
PACTR201106000304583Swedish Institute for Infectious Disease Control24
Recruiting
Phase 1
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9Influenza prophylaxisTherapeutic area: Diseases [C] - Virus Diseases [C02]
CTIS2022-500706-18-01Oslo University Hospital Hf30
Completed
Phase 1
Study to evaluate safety and possible adverse reactions, especially serious, with a vaccine for measles and rubella in healthy subjects.Measles and Rubella
RBR-9hckj4Bio-Manguinhos/Fiocruz/MS
Active, not recruiting
Phase 1
A study of a new vaccine against the MERS virus in adults aged 50 to 70 yearsMiddle East Respiratory Syndrome Coronavirus (MERS-CoV) infectionInfections and Infestations
ISRCTN17936606niversity of Oxford84